









市場
/
株式
/
nasdaq-abbv
/

AbbVie Inc

ABBV

223.683USD

+4.973+2.27%

取引時間（ET）15分遅れの株価

395.33B時価総額

168.37直近12ヶ月PER



AbbVie Inc

223.683

+4.973+2.27%

概要企業名金融分析

概要

企業名

金融

分析

詳細情報 AbbVie Inc 企業名

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It researches and develops, manufactures, commercializes and sells medicines and therapies. Its product portfolio includes immunology, oncology, aesthetics, neuroscience, eye care and Other Specialties. Immunology includes Rheumatology, Dermatology, and Gastroenterology. Oncology includes Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia and Diffuse large B-cell lymphoma. Neuroscience includes Parkinson's disease, Migraine, Movement Disorders, Psychiatric Disorders and Alzheimer’s disease. Eye Care includes Chronic Dry Eye Disease, Glaucoma, Age-Related Retinal Diseases, and Refractive Disorders. Aesthetics includes Botox Cosmetic, The Juvederm Collection of Fillers and others. Its NX-13 for the treatment of ulcerative colitis and Crohn's disease. Its CEL383 for the treatment of inflammatory bowel disease. Its ALIA-1758 for the treatment of patients with Alzheimer's disease.

AbbVie Incの企業情報



企業コードABBV

会社名AbbVie Inc

上場日Jan 02, 2013

最高経営責任者「CEO」Mr. Robert A. Michael, CPA

従業員数55000

証券種類Ordinary Share

決算期末Jan 02

本社所在地1 N Waukegan Rd

都市NORTH CHICAGO

証券取引所NYSE Consolidated

国United States of America

郵便番号60064

電話番号18479327900

ウェブサイトhttps://www.abbvie.com/

企業コードABBV

上場日Jan 02, 2013

最高経営責任者「CEO」Mr. Robert A. Michael, CPA

AbbVie Incの経営陣



会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

183.77K

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

134.63K

+0.90%

Mr. Edward J. (Ed) Rapp

Independent Director

42.95K

+2.88%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.28K

+16.15%

Ms. Roxanne S. Austin, CPA

Lead Independent Director

38.46K

+3.23%

Dr. Robert J. Alpern, M.D.

Independent Director

35.65K

+3.49%

Mr. Frederick H. (Rick) Waddell

Independent Director

28.96K

+4.33%

Ms. Melody B. Meyer

Independent Director

16.50K

+7.87%

Mr. Timothy J. Richmond

Chief Human Resources Officer, Executive Vice President

6.13K

-77.61%

Ms. Jennifer L. Davis

Independent Director

2.52K

+91.00%

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

183.77K

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

134.63K

+0.90%

Mr. Edward J. (Ed) Rapp

Independent Director

42.95K

+2.88%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.28K

+16.15%

Ms. Roxanne S. Austin, CPA

Lead Independent Director

38.46K

+3.23%

Dr. Robert J. Alpern, M.D.

Independent Director

35.65K

+3.49%

収益内訳

通貨: USD更新時刻: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

事業別USD

会社名

収益

比率

Immunology-SKYRIZI

4.42B

28.20%

Immunology-RINVOQ

2.03B

12.93%

Immunology-HUMIRA

1.18B

7.52%

Hematologic Oncology-IMBRUVICA

965.00M

6.15%

Neuroscience-Botox Therapeutic

928.00M

5.92%

他の

6.16B

39.27%

地域別USD

会社名

収益

比率

United States

11.34B

72.31%

International

3.48B

22.18%

All other countries

603.00M

3.84%

Collaboration revenue

260.00M

1.66%

事業別

地域別

事業別USD

会社名

収益

比率

Immunology-SKYRIZI

4.42B

28.20%

Immunology-RINVOQ

2.03B

12.93%

Immunology-HUMIRA

1.18B

7.52%

Hematologic Oncology-IMBRUVICA

965.00M

6.15%

Neuroscience-Botox Therapeutic

928.00M

5.92%

他の

6.16B

39.27%

株主

更新時刻: Sun, Aug 17

株主統計

種類

株主統計

比率

The Vanguard Group, Inc.

10.01%

BlackRock Institutional Trust Company, N.A.

5.21%

State Street Investment Management (US)

4.53%

Geode Capital Management, L.L.C.

2.22%

JP Morgan Asset Management

2.06%

他の

75.97%

株主統計

比率

The Vanguard Group, Inc.

10.01%

BlackRock Institutional Trust Company, N.A.

5.21%

State Street Investment Management (US)

4.53%

Geode Capital Management, L.L.C.

2.22%

JP Morgan Asset Management

2.06%

他の

75.97%

種類

株主統計

比率

Investment Advisor

43.53%

Investment Advisor/Hedge Fund

19.99%

Research Firm

3.07%

Bank and Trust

2.33%

Pension Fund

2.22%

Sovereign Wealth Fund

1.40%

Hedge Fund

1.28%

Insurance Company

0.69%

Family Office

0.20%

他の

25.28%

機関投資家保有株



更新時刻: Wed, Oct 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q3

5311

1.32B

74.55%

-12.59M

2025Q2

5271

1.32B

74.93%

+10.38M

2025Q1

5332

1.32B

74.90%

+11.71M

2024Q4

5219

1.31B

74.47%

+8.91M

2024Q3

4974

1.30B

73.54%

-7.44M

2024Q2

4916

1.30B

73.53%

+2.27M

2024Q1

4930

1.29B

72.58%

-1.47M

2023Q4

4882

1.28B

72.31%

-1.48M

2023Q3

4694

1.27B

71.87%

-12.06M

2023Q2

4688

1.26B

71.51%

-30.42M

詳細を見る

株主動向



会社名

保有株式数

比率

変動額

変動率

日付

The Vanguard Group, Inc.

176.50M

9.99%

+3.35M

+1.94%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

92.10M

5.21%

+1.07M

+1.18%

Jun 30, 2025

State Street Investment Management (US)

80.02M

4.53%

+61.16K

+0.08%

Jun 30, 2025

Geode Capital Management, L.L.C.

39.18M

2.22%

+924.76K

+2.42%

Jun 30, 2025

JP Morgan Asset Management

37.47M

2.12%

+1.87M

+5.24%

Jun 30, 2025

Charles Schwab Investment Management, Inc.

26.78M

1.52%

+1.52M

+6.01%

Jun 30, 2025

Capital Research Global Investors

25.27M

1.43%

-8.24M

-24.60%

Jun 30, 2025

Morgan Stanley Smith Barney LLC

23.51M

1.33%

+254.93K

+1.10%

Jun 30, 2025

Norges Bank Investment Management (NBIM)

23.10M

1.31%

-1.99M

-7.94%

Jun 30, 2025

Fidelity Management & Research Company LLC

19.65M

1.11%

-1.78M

-8.30%

Jun 30, 2025

詳細を見る

配当金



過去5年間の配当金総支払額は 48.58B 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

Oct 30, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025

Jan 15, 2025

Feb 14, 2025

Jan 15, 2025

Sep 06, 2024

ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option

Oct 15, 2024

Nov 15, 2024

Oct 15, 2024

Jun 21, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option

Jul 15, 2024

Aug 15, 2024

Jul 15, 2024

Feb 15, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option

Apr 15, 2024

May 15, 2024

Apr 12, 2024

Oct 27, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Feb 15, 2024 going ex on Jan 12, 2024 with reinvestment option

Jan 16, 2024

Feb 15, 2024

Jan 12, 2024

Sep 11, 2023

ABBV.NB Final Cash Dividend of gross USD 1.48 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option

Oct 13, 2023

Nov 15, 2023

Oct 12, 2023

Jun 22, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option

Jul 14, 2023

Aug 15, 2023

Jul 13, 2023

Feb 16, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option

Apr 14, 2023

May 15, 2023

Apr 13, 2023

Oct 28, 2022

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option

Jan 13, 2023

Feb 15, 2023

Jan 12, 2023

Sep 09, 2022

ABBV.NB Final Cash Dividend of gross USD 1.41 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option

Oct 14, 2022

Nov 15, 2022

Oct 13, 2022

詳細を見る

株式分割



日付

種類

比率

データなし

日付

種類

比率

データなし

KeyAI



AbbVie Inc

詳細情報 AbbVie Inc 企業名

AbbVie Incの企業情報

AbbVie Incの経営陣

収益内訳

株主

機関投資家保有株

株主動向

関連ETF

配当金

株式分割